Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126677351 | 12667735 | 1 | I | 20150605 | 20160809 | 20160819 | 20160819 | EXP | US-BAYER-2016-157232 | BAYER | 0.00 | M | Y | 0.00000 | 20160819 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126677351 | 12667735 | 1 | PS | BAYER LOW DOSE | ASPIRIN | 1 | 81 MG, UNK | 999999 | 81 | MG | GASTRO-RESISTANT TABLET | ||||||||
| 126677351 | 12667735 | 2 | SS | CHOLECALCIFEROL | CHOLECALCIFEROL | 1 | Oral | 1000 IU, OW | U | 0 | 1000 | IU | TABLET | /wk | |||||
| 126677351 | 12667735 | 3 | SS | METOPROLOL. | METOPROLOL | 1 | Oral | 50 MG, QD | U | 0 | 50 | MG | TABLET | QD | |||||
| 126677351 | 12667735 | 4 | SS | ISOSORBIDE MONONITRATE. | ISOSORBIDE MONONITRATE | 1 | Oral | 30 MG, QD | U | 0 | 30 | MG | QD | ||||||
| 126677351 | 12667735 | 5 | SS | PRINIVIL | LISINOPRIL | 1 | Oral | 10 MG, QD | U | 0 | 10 | MG | QD | ||||||
| 126677351 | 12667735 | 6 | SS | PREVACID | LANSOPRAZOLE | 1 | Oral | 30 MG, QD | U | 0 | 30 | MG | QD | ||||||
| 126677351 | 12667735 | 7 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, UNK | U | 0 | 75 | MG | |||||||
| 126677351 | 12667735 | 8 | SS | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 80 MG, QD | U | 0 | 80 | MG | QD | ||||||
| 126677351 | 12667735 | 9 | SS | NEURONTIN | GABAPENTIN | 1 | Oral | 300 MG, BID | U | 0 | 300 | MG | BID | ||||||
| 126677351 | 12667735 | 10 | SS | TRANXENE T-TAB | CLORAZEPATE DIPOTASSIUM | 1 | Oral | 7.5 MG, QD | U | 0 | 7.5 | MG | QD | ||||||
| 126677351 | 12667735 | 11 | C | REVLIMID | LENALIDOMIDE | 1 | Oral | 25 MG, UNK | A0610A | 0 | 25 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126677351 | 12667735 | 1 | Anticoagulant therapy |
| 126677351 | 12667735 | 3 | Hypertension |
| 126677351 | 12667735 | 4 | Prophylaxis |
| 126677351 | 12667735 | 5 | Hypertension |
| 126677351 | 12667735 | 6 | Dyspepsia |
| 126677351 | 12667735 | 7 | Anticoagulant therapy |
| 126677351 | 12667735 | 8 | Blood cholesterol |
| 126677351 | 12667735 | 9 | Neuropathy peripheral |
| 126677351 | 12667735 | 11 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126677351 | 12667735 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126677351 | 12667735 | Pyrexia | |
| 126677351 | 12667735 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126677351 | 12667735 | 11 | 20150605 | 0 |